

Ami A Shah, Mhs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2940428/publications.pdf>

Version: 2024-02-01

90
papers

3,303
citations

172386

29
h-index

168321

53
g-index

94
all docs

94
docs citations

94
times ranked

3770
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases. <i>Clinical Infectious Diseases</i> , 2022, 74, 427-436.	2.9	15
2	Patients with checkpoint inhibitor-induced inflammatory arthritis do not become seropositive for anti-cyclic citrullinated peptide when followed over time. <i>ACR Open Rheumatology</i> , 2022, 4, 83-84.	0.9	5
3	Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 163-174.	0.9	3
4	Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 738-740.	0.5	20
5	Diastolic Dysfunction in Systemic Sclerosis: Risk Factors and Impact on Mortality. <i>Arthritis and Rheumatology</i> , 2022, 74, 849-859.	2.9	6
6	Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases. <i>Lancet Rheumatology</i> , The, 2022, 4, e382-e384.	2.2	9
7	Troponin elevation independently associates with mortality in systemic sclerosis.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
8	Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis. <i>Lancet Rheumatology</i> , The, 2022, 4, e462-e464.	2.2	6
9	Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease. <i>Rheumatology</i> , 2022, 61, e302-e304.	0.9	4
10	Advances at the interface of cancer and systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 50-57.	1.0	4
11	Primary central nervous system lymphoma in scleroderma: A case series. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 214-219.	1.0	0
12	Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1005-1013.	2.9	21
13	Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures?. <i>Clinical Rheumatology</i> , 2021, 40, 965-971.	1.0	7
14	Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex. <i>Arthritis and Rheumatology</i> , 2021, 73, 315-323.	2.9	19
15	Essential Hypertension Worsens Left Ventricular Contractility in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 1299-1306.	1.0	3
16	Autoantibodies targeting telomere-associated proteins in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 912-919.	0.5	19
17	Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection. <i>Arthritis Research and Therapy</i> , 2021, 23, 64.	1.6	9
18	Effect of Coping Strategies on Patient and Physician Perceptions of Disease Severity and Disability in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 1569-1573.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Exercise right ventricular ejection fraction predicts right ventricular contractile reserve. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 504-512.	0.3	15
20	Anti-ANP32A antibodies in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-221354.	0.5	0
21	Predicting clinical events using Bayesian multivariate linear mixed models with application to scleroderma. <i>BMC Medical Research Methodology</i> , 2021, 21, 249.	1.4	0
22	Feasibility and acceptability of using a meditation app in adults with rheumatic disease. <i>Explore: the Journal of Science and Healing</i> , 2021, , .	0.4	0
23	More Than Skin Deep: Bringing Precision Medicine to Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 383-385.	2.9	3
24	Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. <i>Clinical Rheumatology</i> , 2020, 39, 93-102.	1.0	8
25	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 379-386.	0.5	97
26	Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1). <i>Clinical Rheumatology</i> , 2020, 39, 1199-1205.	1.0	6
27	Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps. <i>BMC Rheumatology</i> , 2020, 4, 32.	0.6	18
28	The Utility of Plasma Vascular Biomarkers in Systemic Sclerosis: A Prospective Longitudinal Analysis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1341-1349.	2.9	3
29	Definition of Naturally Processed Peptides Reveals Convergent Presentation of Autoantigenic Topoisomerase I Epitopes in Scleroderma. <i>Arthritis and Rheumatology</i> , 2020, 72, 1375-1384.	2.9	12
30	Cancer and Scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 551-564.	0.8	14
31	Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1892-1896.	2.9	36
32	Response to: "Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation" by Braaten et al: another point of view™ by Cappelli et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2019-216892.	0.5	1
33	The relationships between cancer and autoimmune rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101472.	1.4	30
34	Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis. <i>Immunological Reviews</i> , 2020, 294, 106-123.	2.8	24
35	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338.	0.5	140
36	<i>HLA</i> and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 552-562.	3.3	52

#	ARTICLE	IF	CITATIONS
37	Epigenetic activation and memory at a <i>TGFB2</i> enhancer in systemic sclerosis. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	47
38	Protective Effect Against Cancer of Antibodies to the Large Subunits of Both <i>RNA</i> Polymerases I and <i>III</i> in Scleroderma. <i>Arthritis and Rheumatology</i> , 2019, 71, 1571-1579.	2.9	34
39	Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. <i>Nature Communications</i> , 2019, 10, 1128.	5.8	28
40	Morphea and systemic sclerosis are associated with an increased risk for melanoma and nonmelanoma skin cancer. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1449-1451.	0.6	21
41	Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2019, 21, 68.	2.1	20
42	Estimating autoantibody signatures to detect autoimmune disease patient subsets. <i>Biostatistics</i> , 2019, 20, 30-47.	0.9	3
43	Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. <i>Rheumatology</i> , 2019, 58, 476-480.	0.9	77
44	Anti- <i>RNPC</i> (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate to Severe Gastrointestinal Dysmotility. <i>Arthritis Care and Research</i> , 2019, 71, 1164-1170.	1.5	28
45	A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 712-720.	2.3	71
46	Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2018-212999.	0.5	60
47	Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer. <i>Arthritis Care and Research</i> , 2018, 70, 1517-1524.	1.5	16
48	Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Interinstitutional Adult Rheumatology Mentoring Program. <i>Arthritis Care and Research</i> , 2018, 70, 445-453.	1.5	12
49	Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. , 2018, 6, 104.		55
50	Vascular complications in systemic sclerosis: a prospective cohort study. <i>Clinical Rheumatology</i> , 2018, 37, 2429-2437.	1.0	15
51	Brief Report: Whole Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. <i>Arthritis and Rheumatology</i> , 2018, 70, 1654-1660.	2.9	10
52	Brief Report: Anti- <i>RNPC</i> Antibodies As a Marker of Cancer-Associated Scleroderma. <i>Arthritis and Rheumatology</i> , 2017, 69, 1306-1312.	2.9	61
53	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 1915-1916.	2.9	0
54	Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality. <i>Arthritis Care and Research</i> , 2017, 69, 1764-1770.	1.5	35

#	ARTICLE	IF	CITATIONS
55	Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. <i>Immunotherapy</i> , 2017, 9, 5-8.	1.0	20
56	Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1701436.	3.1	37
57	Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 65-78.	0.8	101
58	Clinical and serological features of systemic sclerosis in a multicenter African American cohort. <i>Medicine (United States)</i> , 2017, 96, e8980.	0.4	78
59	Mechanistic and clinical insights at the scleroderma-cancer interface. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 153-159.	1.0	21
60	Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 71-74.	0.4	10
61	Anti-Interferon-Inducible Protein 16 Antibodies Associate With Digital Gangrene in Patients With Scleroderma. <i>Arthritis and Rheumatology</i> , 2016, 68, 1262-1271.	2.9	13
62	Exhaled Nitric Oxide in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis. <i>Pulmonary Circulation</i> , 2016, 6, 545-550.	0.8	8
63	Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 53-62.	1.4	25
64	Thrombotic complications after radial arterial line placement in systemic sclerosis: A case series. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 196-199.	1.6	10
65	The Recurrence of Digital Ulcers in Patients with Systemic Sclerosis after Discontinuation of Oral Treprostinil. <i>Journal of Rheumatology</i> , 2016, 43, 1665-1671.	1.0	17
66	Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7526-E7534.	3.3	75
67	Unique Abnormalities in Right Ventricular Longitudinal Strain in Systemic Sclerosis Patients. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	1.3	67
68	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 20.	1.6	18
69	Symptomatic and Electrodiagnostic Features of Peripheral Neuropathy in Scleroderma. <i>Arthritis Care and Research</i> , 2016, 68, 1150-1157.	1.5	17
70	Cancer and scleroderma. <i>Current Opinion in Rheumatology</i> , 2015, 27, 563-570.	2.0	68
71	Barriers to and Facilitators of a Career as a Physician-Scientist Among Rheumatologists in the US. <i>Arthritis Care and Research</i> , 2015, 67, 1191-1201.	1.5	17
72	Spectrum of Muscle Histopathologic Findings in Forty-two Scleroderma Patients With Weakness. <i>Arthritis Care and Research</i> , 2015, 67, 1416-1425.	1.5	56

#	ARTICLE	IF	CITATIONS
73	Molecular Subsetting of Interferon Pathways in Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2015, 67, 2437-2446.	2.9	115
74	Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 136.	0.4	7
75	Examination of Autoantibody Status and Clinical Features Associated With Cancer Risk and Cancer-Associated Scleroderma. <i>Arthritis and Rheumatology</i> , 2015, 67, 1053-1061.	2.9	93
76	Intravenous Immunoglobulin May Be an Effective Therapy for Refractory, Active Diffuse Cutaneous Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 236-242.	1.0	54
77	Review: Cancer-Induced Autoimmunity in the Rheumatic Diseases. <i>Arthritis and Rheumatology</i> , 2015, 67, 317-326.	2.9	90
78	Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S123-6.	0.4	2
79	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2014, 33, 207-214.	1.0	48
80	Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer. <i>Science</i> , 2014, 343, 152-157.	6.0	358
81	Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. <i>Arthritis Research and Therapy</i> , 2014, 16, R53.	1.6	153
82	My Approach to the Treatment of Scleroderma. <i>Mayo Clinic Proceedings</i> , 2013, 88, 377-393.	1.4	51
83	Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1136-1140.	0.5	19
84	Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. <i>Arthritis Research and Therapy</i> , 2013, 15, R54.	1.6	25
85	Race and Association With Disease Manifestations and Mortality in Scleroderma. <i>Medicine (United States)</i> 94(1):1-10. doi:10.1093/med/94.1.1	0.4	100
86	Cancer and systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 530-535.	2.0	47
87	Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. <i>Arthritis and Rheumatism</i> , 2010, 62, 2787-2795.	6.7	180
88	Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial Hypertension. <i>Journal of Rheumatology</i> , 2010, 37, 98-104.	1.0	88
89	Laughter-induced Syncope. <i>American Journal of Medicine</i> , 2010, 123, 609-611.	0.6	6
90	Troponin elevation independently associates with mortality in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1